Evithrom Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high surgical blood loss risks, need for fast acting hemostasis, early use of thrombin products, increasing trauma cases, adoption in orthopedic procedures.

The growth in the forecast period can be attributed to growth in surgical interventions, rising accident and trauma rates, expanding hospital infrastructure, innovation in thrombin formulations, increased focus on surgical safety. Major trends in the forecast period include growing use of topical hemostatic agents, rising demand in cardiovascular surgeries, expansion of trauma and emergency care, preference for rapid clot formation solutions, increased adoption of human thrombin products.

The increasing number of surgical procedures is expected to drive the growth of the evithrom market in the coming years. Surgical procedures involve medical operations or interventions that physically alter or manipulate tissues and organs in the body. The growth in surgical procedures is primarily driven by advancements in medical technology, which make surgeries safer and more efficient, as well as the rising prevalence of chronic diseases that require surgical interventions. Evithrom is used during surgeries to control bleeding by promoting clot formation and enhancing hemostasis, particularly in high-risk procedures such as cardiovascular or orthopedic surgeries. For example, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based non-profit organization, reported that liposuction remained the most common surgical procedure in 2023, with over 2.2 million performed, while face and head procedures rose by 19.6% to over 6.5 million cases. Therefore, the growing number of surgical procedures is supporting the growth of the evithrom market.

The rising prevalence of spinal-related injuries is also expected to propel the growth of the evithrom market. Spinal-related injuries involve damage to the spinal cord, vertebrae, discs, or surrounding tissues, caused by accidents, falls, diseases, or other medical conditions. The increase in spinal injuries is driven by higher road traffic accidents and an aging population prone to conditions like osteoporosis, which increase fracture risk. Evithrom is used in spinal surgeries to control bleeding by promoting clot formation at the surgical site, helping manage blood loss during procedures such as spinal fusion or decompression. For example, in October 2024, the Congressionally Directed Medical Research Programs, a US-based clinical research platform, reported that approximately 300,000 people in the U.S. are living with spinal cord injuries (SCI), with over 17,000 new cases annually, and numbers continue to rise. Therefore, the increasing prevalence of spinal-related injuries is driving the growth of the evithrom market.

The growing adoption of personalized medicine is also expected to support the expansion of the evithrom market. Personalized medicine tailors treatment strategies to the individual characteristics of patients, including genetic makeup, environment, and lifestyle, to deliver more precise and effective outcomes. The rise of personalized medicine is driven by advancements in genomic technologies, increased understanding of molecular biology, wider availability of precision diagnostics, and demand for targeted therapies that improve outcomes while reducing side effects. Evithrom, as a human thrombin product, supports personalized medicine by enabling precise hemostatic management tailored to individual patient profiles, ensuring optimal bleeding control during surgery. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit, reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, a substantial increase from six approvals in 2022. Therefore, the growing adoption of personalized medicine is driving the evithrom market.

Major companies operating in the evithrom market are Johnson & Johnson Inc.

North America was the largest region in the evithrom market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the evithrom market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the evithrom market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the evithrom market by increasing costs associated with importing human thrombin, fibrinogen, and sterile formulation materials. These impacts are more pronounced in hospital and clinic distribution channels across import dependent regions such as asia pacific and latin america. Higher costs can affect product affordability and procurement volumes. At the same time, tariffs are encouraging domestic production of hemostatic agents and improving long term supply chain resilience.

The evithrom market research report is one of a series of new reports that provides evithrom market statistics, including evithrom industry global market size, regional shares, competitors with a evithrom market share, detailed evithrom market segments, market trends and opportunities, and any further data you may need to thrive in the evithrom industry. This evithrom market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Evithrom is a topical hemostatic agent made of human thrombin and fibrinogen, intended to control bleeding during surgical procedures. It is applied in a variety of surgeries, including cardiovascular and orthopedic operations, to encourage clot formation and prevent excessive bleeding.

The main types of indications for evithrom are surgical hemostasis and trauma care. Surgical hemostasis involves techniques and measures used during operations to stop bleeding and achieve blood vessel closure. It is available in formulations containing bovine thrombin, human thrombin, and recombinant thrombin, and is distributed through hospitals, clinics, diagnostic centers, and online pharmacies.

The evithrom market consists of sales of products including albumin, immunoglobulins, prothrombin complex concentrates, C1 esterase inhibitors, and fibrin sealants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.